Neuroblastoma Clinical Trials

39 studies are recruiting for neuroblastoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

   This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuxima…

   Stage

   Phase 3

   Ages

   Up to 30

   Site

   Children's Hospital of Alabama, Birmingham, Alabama

   Locations

   180 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06172296 on ClinicalTrials.gov

2. Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

   Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastom…

   Stage

   Phase 1

   Ages

   0 to 25

   Site

   Children's Hospital Los Angeles ( Site 1006), Los Angeles, California

   Locations

   71 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06395103 on ClinicalTrials.gov

3. Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

   Background: * Endocrine neoplasms (tumors) are among the fastest growing tumors in incidence in the United States. Furthermore, it is often difficult to distinguish between benign or malignant tumors in cancers of the thyroid, parathyroid, adrenal gland, and pancreas. More research is needed to imp…

   Stage

   Not phased

   Ages

   4 and older

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT01005654 on ClinicalTrials.gov

4. Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

   This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant period to treat pediatric patients with relapsed or…

   Stage

   Phase 1

   Ages

   0 to 21

   Site

   University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

   Run by

   University of Wisconsin, Madison

   See if you can join NCT02508038 on ClinicalTrials.gov

5. Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

   This is a phase II single center study to administer two courses of myeloablative consolidation chemotherapy each followed by an autologous peripheral blood stem cell (PBSC) rescue in patients with high-risk neuroblastoma who have completed induction chemotherapy (independent of this study). Ideall…

   Stage

   Phase 2

   Ages

   Up to 30

   Site

   Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota

   Run by

   Masonic Cancer Center, University of Minnesota

   See if you can join NCT02605421 on ClinicalTrials.gov

6. International PPB/DICER1 Registry

   PPB has strong genetic implications, with a unique set of conditions in an individual or their family, occurring mostly in childhood and adolescence. The International PPB/DICER1 Registry first reported DICER1 germline loss-of-function variations in individuals with PPB and their family members. Co…

   Stage

   Not phased

   Ages

   Up to 100

   Site

   Children's Minnesota, Minneapolis, Minnesota

   Run by

   Children's Hospitals and Clinics of Minnesota

   See if you can join NCT03382158 on ClinicalTrials.gov

7. Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma

   Background: Neuroblastoma is a type of cancer that causes tumors in nerves. It affects mainly infants and toddlers, and it causes about 15 percent of cancer-related deaths in children. Objective: To test a new drug (rhIL-15), combined with 3 standard cancer drugs, in people with neuroblastoma. Elig…

   Stage

   Phase 1

   Ages

   3 to 35

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06995872 on ClinicalTrials.gov

8. Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

   Background: - Laboratory investigators who are studying common childhood cancers are interested in developing a tissue repository to collect and store blood, serum, tissue, urine, or tumors of children who have cancer or adults who have common childhood cancers. To develop this repository, addition…

   Stage

   Not phased

   Ages

   0 and older

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Locations

   5 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT01109394 on ClinicalTrials.gov

9. A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

   The purpose of this study is to test which treatment schedule of β-glucan with bivalent vaccine is more effective for participants with high-risk neuroblastoma that is in complete remission.

   Stage

   Phase 2

   Ages

   Any age

   Site

   Memorial Sloan Kettering at Basking Ridge (Consent only), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06057948 on ClinicalTrials.gov

10. Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

    This is a Phase 1 study of the combination of two drugs: MM-398 and Cyclophosphamide. The goal is to find the highest dose of MM-398 that can be given safely when it is used together with the chemotherapy drug Cyclophosphamide.

    Stage

    Phase 1

    Ages

    1 to 20

    Site

    Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

    Locations

    5 in total

    Run by

    South Plains Oncology Consortium

    See if you can join NCT02013336 on ClinicalTrials.gov

11. Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

    The purpose of this study is to evaluate the investigational drug, silmitasertib (a pill taken by mouth), in combination with FDA approved drugs for solid tumors. An investigational drug is one that has not been approved by the U.S. Food \& Drug Administration (FDA), or any other regulatory authori…

    Stage

    Phase 1

    Ages

    Up to 30

    Site

    University of Alabama/Children's of Alabama, Birmingham, Alabama

    Locations

    24 in total

    Run by

    Milton S. Hershey Medical Center

    See if you can join NCT06541262 on ClinicalTrials.gov

12. Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome

    The purpose of this study is to find out the genetic and biochemical makeup of your neuroblastic tumor, which influences its aggressiveness and the suitable therapy. These research studies include surface marker analysis, cytogenetics, cancer genes,genome sequencing, tumor growth-related genes and …

    Stage

    Not phased

    Ages

    Any age

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT00588068 on ClinicalTrials.gov

13. MCT for the Harvard/UCSF ROBIN Center

    The goal of the Molecular Characterization Trial (MCT) is to obtain biological specimens and data resources from patients enrolled on prospective trials, to ensure that the Harvard/UCSF ROBIN Center accomplishes its key objective of advancing our understanding of the biological mechanisms that unde…

    Stage

    Not phased

    Ages

    Any age

    Site

    University of California, San Francisco, San Francisco, California

    Locations

    2 in total

    Run by

    Brigham and Women's Hospital

    See if you can join NCT06000787 on ClinicalTrials.gov

14. A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma

    The purpose of the study is to explore the combination of a bivalent vaccine, a sugar called beta-glucan (β-glucan), and a protein called granulocyte-macrophage colony stimulating factor (GM-CSF) as an effective treatment for people with high-risk neuroblastoma that is in complete remission. The co…

    Stage

    Phase 2

    Ages

    Any age

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT04936529 on ClinicalTrials.gov

15. Biomarkers of Resiliency In Childhood Cancer Surgery

    This observational study is to better understand how children and their families recover after the stress of major surgery for cancer so that investigators can create ways to improve resilience during recovery. The main questions it aims to answer are: 1. Can information obtained from patients and …

    Stage

    Not phased

    Ages

    3 to 25

    Site

    Mayo Clinic, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT06674811 on ClinicalTrials.gov

16. Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

    A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Newly Diagnos…

    Stage

    Phase 2

    Ages

    Up to 22

    Site

    University of Alabama/Children's of Alabama, Birmingham, Alabama

    Locations

    28 in total

    Run by

    Giselle Sholler

    See if you can join NCT02559778 on ClinicalTrials.gov

17. Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

    The purpose of this study is to evaluate the investigational oral drug AMXT 1501 in combination with oral eflornithine (DFMO). An investigational drug is one that has not been approved by the U.S. Food \& Drug Administration (FDA), or any other regulatory authorities around the world for use alone …

    Stage

    Phase 1

    Ages

    Up to 26

    Site

    University of Alabama/Children's of Alabama, Birmingham, Alabama

    Locations

    14 in total

    Run by

    Milton S. Hershey Medical Center

    See if you can join NCT06465199 on ClinicalTrials.gov

18. Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

    The purpose of this study is to evaluate the investigational drug, tipifarnib (a pill taken by mouth), in combination with the Food and Drug Administration (FDA) approved drug, naxitimab, administered intravenously (IV; a liquid that continuously goes into your body through a tube that has been pla…

    Stage

    Phase 2

    Ages

    1 to 21

    Site

    Arkansas Children's Hospital, Little Rock, Arkansas

    Locations

    12 in total

    Run by

    Giselle Sholler

    See if you can join NCT06540963 on ClinicalTrials.gov

19. B7-H3.CD28Z.CART in Solid Tumors

    The goal of this research study is to test if a new cell therapy (B7-H3.CD28Z.CART / B7-H3 CAR T cells) is safe and effective in treating children and young adults with solid cancers whose tumors have returned or stopped responding to standard treatments (relapsed or refractory) and have been ident…

    Stage

    Phase 1

    Ages

    0 to 30

    Site

    Dana Farber Cancer Institite, Boston, Massachusetts

    Run by

    Robbie Majzner

    See if you can join NCT07358260 on ClinicalTrials.gov

20. N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

    The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.

    Stage

    Phase 2

    Ages

    1 to 19

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06528496 on ClinicalTrials.gov

21. Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

    This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lor…

    Stage

    Phase 3

    Ages

    1 to 30

    Site

    Children's Hospital of Alabama, Birmingham, Alabama

    Locations

    164 in total

    Run by

    Children's Oncology Group

    See if you can join NCT03126916 on ClinicalTrials.gov

22. Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

    This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may hel…

    Stage

    Phase 1

    Ages

    1 to 30

    Site

    Children's Hospital of Alabama, Birmingham, Alabama

    Locations

    21 in total

    Run by

    Children's Oncology Group

    See if you can join NCT04851119 on ClinicalTrials.gov

23. Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma

    The goal of this study is to demonstrate that cytokine-induced memory-like natural killer cells (CIML-NK cells) can be generated from donor cells and infused safely into patients with relapsed or refractory neuroblastoma during dinutuximab-based therapy.

    Stage

    Phase 2

    Ages

    1 to 39

    Site

    Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

    Run by

    Children's Hospital Medical Center, Cincinnati

    See if you can join NCT07635056 on ClinicalTrials.gov

24. Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

    This is a phase I dose-escalation study to determine the safety and feasibility of autologous CAR-TA T cells (B7-H3 CAR+ T cells administered with DNR-PRAME Tumor Antigen-specific T cells) following lymphodepleting chemotherapy in participants with relapsed/refractory rhabdomyosarcoma, Ewing sarcom…

    Stage

    Phase 1

    Ages

    1 to 23

    Site

    Children's National Hospital, Washington D.C., District of Columbia

    Locations

    2 in total

    Run by

    Children's National Research Institute

    See if you can join NCT07172958 on ClinicalTrials.gov

25. Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

    This is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard induction therapy. The initial chemotherapy will include 5 cycles of multi-agent chemotherapy. Naxitamab will be ad…

    Stage

    Phase 2

    Ages

    1 to 21

    Site

    University of Alabama/Children's of Alabama, Birmingham, Alabama

    Locations

    26 in total

    Run by

    Giselle Sholler

    See if you can join NCT05489887 on ClinicalTrials.gov